Mayo Clinic Finds DNA Aptamers That Flag Senescent Cells After Screening 100 Trillion Sequences
Updated
Updated · ScienceDaily · May 15
Mayo Clinic Finds DNA Aptamers That Flag Senescent Cells After Screening 100 Trillion Sequences
2 articles · Updated · ScienceDaily · May 15
Mayo Clinic researchers reported in Aging Cell that synthetic DNA aptamers selectively bound senescent “zombie cells” in mouse-cell experiments, offering a new way to identify cells that have been hard to distinguish in living tissue.
More than 100 trillion random DNA sequences were screened to isolate rare aptamers that attached to proteins linked to senescence, establishing proof of principle that the molecules can separate senescent from healthy cells.
Several aptamers bound a fibronectin variant on mouse-cell surfaces, a clue that could help define biological features of senescent cells beyond current nonuniversal markers.
The work began with a graduate-student idea born from a campus conversation, then expanded across multiple Mayo labs as early results encouraged broader testing and microscopy analysis.
Researchers said human use still needs further study, but aptamers could eventually provide a cheaper, more adaptable alternative to antibodies and even deliver therapies directly to senescent cells.
As rival DNA technologies emerge, will this breakthrough truly become the ultimate weapon against age-related diseases?
Could synthetic DNA be programmed to repair aging 'zombie cells' instead of just identifying them for destruction?
If these 'zombie cells' have hidden protective roles, what unforeseen health problems could arise from eliminating them?
DNA Aptamers Unlock Precise Identification of Senescent "Zombie" Cells: A Breakthrough for Aging and Disease Therapies
Overview
Researchers at Mayo Clinic have developed a new way to identify senescent, or 'zombie,' cells using DNA aptamers. This breakthrough solves a major problem in biomedical research: the lack of reliable markers to find these harmful cells, which are linked to aging and disease. The idea came from graduate students Keenan Pearson and Sarah Jachim, who faced initial skepticism but gained support from mentors like Dr. Maher and Dr. Darren Baker. Their collaboration quickly led to success, showing that aptamer technology can accurately flag senescent cells and may help create targeted therapies in the future.